Abstract

Extracellular vesicles (EVs) have been lauded as next-generation medicines, but very few EV-based therapeutics have progressed to clinical use. Limited clinical translation is largely due to technical barriers that hamper our ability to mass produce EVs, i.e., to isolate, purify, and characterize them effectively. Technical limitations in comprehensive characterization of EVs lead to unpredicted biological effects of EVs. Here, using a range of optical and non-optical techniques, we showed that the differences in molecular composition of EVs isolated using two isolation methods correlated with the differences in their biological function. Our results demonstrated that the isolation method determines the composition of isolated EVs at single and sub-population levels. Besides the composition, we measured for the first time the dry mass and predicted sedimentation of EVs. These parameters were likely to contribute to the biological and functional effects of EVs on single cell and cell cultures. We anticipate that our new multiscale characterization approach, which goes beyond traditional experimental methodology, will support fundamental understanding of EVs as well as elucidate the functional effects of EVs in in vitro and in vivo studies. Our findings and methodology will be pivotal for developing optimal isolation methods and establishing EVs as mainstream therapeutics and diagnostics. This innovative approach is applicable to a wide range of sectors including biopharma and biotechnology as well as to regulatory agencies.

Highlights

  • Current medicine has only taken us so far in reducing disease and the tissue damage that it causes

  • We showed that the amount of nucleic acid in the spectra of Extracellular vesicles (EVs) isolated using ultracentrifugation was smaller than tangential flow filtration (TFF) regardless of the origin of EVs, which was consistent with the nano-flow cytometry (nFCM) result

  • It has not been clear whether different isolation methods extract different sub-populations of EVs, which would impact on their downstream applications

Read more

Summary

Introduction

Current medicine has only taken us so far in reducing disease and the tissue damage that it causes. EVs are membrane-surrounded nanoscale structures secreted ubiquitously by cells They contain multiple substances that influence the function of surrounding cells (Lötvall et al, 2014; Iraci et al, 2016). EVs have key advantages including low immunogenicity, no ability to self-replicate (no risk of cancer), high resistance to hostile environments, and improved bioactivity and stability upon storage (Piffoux et al, 2017). Despite all these potential advantages, very few EV applications have progressed to clinical use (Yekula et al, 2020)

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call